Allen discusses the advancement of Alzheimer’s disease treatment with Leqembi, but also highlights its factors of concern, such as safety, cost, and accessibility.
All articles by Arthur Allen
Allen investigated the reaction to the FDA approval of Leqembi (lecanemab), as support for the drug has been met with heavy criticism. Praised by some scientists and criticized by many others, the rollout of the Alzheimer drug raises questions of safety and potential racial disparity in elder care.
Latest News Your top articles for Sunday
Haymarket Medical NetworkTop Picks